Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Furosemide controlled release - scPharmaceuticals

Next Previous
X
Search
Drug Profile

Furosemide controlled release - scPharmaceuticals

Alternative Names: Furoscix; Furoscix Infusor - scPharmaceuticals; Furosemide injection - scPharmaceuticals; Furosemide micropump patch - scPharmaceuticals/Sensile Medical; sc2Wear furosemide Infusor - scPharmaceuticals/Sensile Medical; SCP-101; SCP-111

Latest Information Update: 10 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator scPharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Skin disorder therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Loop diuretics; Symporter inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic heart failure
  • Preregistration Oedema

Most Recent Events

  • 24 Apr 2024 scPharmaceuticals initiates its enrolment in a pivotal pharmacokinetic trial in an unknown location (SC)
  • 19 Apr 2024 scPharmaceuticals initiates the phase I trial for Heart failure (In volunteers) in USA (SC, IV) (NCT06167707)
  • 29 Mar 2024 FDA assigns PDUFA action date of 31/03/2025 for Furosemide controlled release for Edema in patients with chronic kidney disease (CKD)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top